{
  "first_published_at": "2007-12-01", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON084698", 
  "title": "Talc for pleurodesis: adverse effects", 
  "tags": "{\"parsed_therapeutic\": [\"respiratory-disease-allergy\"], \"Audience:\": [\"Secondary care\"], \"Therapeutic area:\": [\"Respiratory disease and allergy\"]}", 
  "_document_number": 310, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "respiratory-disease-allergy"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Talc for pleurodesis: adverse effects</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: December 2007</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--Users should be aware of an increased risk of adverse events, including acute respiratory distress syndrome, with talc preparations of small particle size-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>We have recently advised that talc preparations for pleurodesis are to be considered as medicinal products. At present, no such products are licensed. Therefore they may be prescribed only for the special clinical needs of individual patients on the direct personal responsibility of the prescriber. Users should be aware of an increased risk of adverse events, including acute respiratory distress syndrome, with talc preparations of small particle size.</p><p>For further information see <a href=\"http://www.mhra.gov.uk/Publications/Safetywarnings/DrugAlerts/CON2032665\">Drug safety information: MHRA statement on talc preparations for pleurodesis</a></p><p>&nbsp;</p><p><em>Article citation: Drug Safety Update December 2007; Volume 1 Issue 5: 15</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>We have recently advised that talc preparations for pleurodesis are to be considered as medicinal products. At present, no such products are licensed. Therefore they may be prescribed only for the special clinical needs of individual patients on the direct personal responsibility of the prescriber. Users should be aware of an increased risk of adverse events, including acute respiratory distress syndrome, with talc preparations of small particle size.</p><p>For further information see <a href=\"http://www.mhra.gov.uk/Publications/Safetywarnings/DrugAlerts/CON2032665\">Drug safety information: MHRA statement on talc preparations for pleurodesis</a></p><p>&#160;</p><p><em>Article citation: Drug Safety Update December 2007; Volume 1 Issue 5: 15</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2007-12-01", 
  "date_last_modified": "2010-08-27", 
  "_assets": [], 
  "_item_id": 310, 
  "summary": "", 
  "body": "Article date: December 2007\n\nWe have recently advised that talc preparations for pleurodesis are to be considered as medicinal products. At present, no such products are licensed. Therefore they may be prescribed only for the special clinical needs of individual patients on the direct personal responsibility of the prescriber. Users should be aware of an increased risk of adverse events, including acute respiratory distress syndrome, with talc preparations of small particle size.\n\nFor further information see [Drug safety information: MHRA statement on talc preparations for pleurodesis](http://www.mhra.gov.uk/Publications/Safetywarnings/DrugAlerts/CON2032665)\n\nÂ \n\nArticle citation: Drug Safety Update December 2007; Volume 1 Issue 5: 15\n"
}